U.S., June 18 -- ClinicalTrials.gov registry received information related to the study (NCT07025239) titled 'QL1706 Injection Plus Bevacizumab and XELOX vs Placebo Plus Bevacizumab and XELOX as First-Line Treatment of Unresectable Metastatic Colorectal Cancer' on June 09.
Brief Summary: The purpose of this study is to evaluate the efficacy and safety of QL1706 Injection in combination with bevacizumab and XELOX compared with placebo in combination with bevacizumab and XELOX for first-line treatment in patients with unresectable mCRC.
Study Start Date: July, 2025
Study Type: INTERVENTIONAL
Condition:
Metastatic Colorectal Cancer
Intervention:
DRUG: QL1706
QL1706 will be administered by IV infusion at 5mg/kg on Day 1 of each 21-day cy...